Illumina, Inc. (ILMN) Shares Sold by Meag Munich Ergo Kapitalanlagegesellschaft MBH

Meag Munich Ergo Kapitalanlagegesellschaft MBH lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 41.3% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,580 shares of the life sciences company’s stock after selling 3,923 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft MBH’s holdings in Illumina were worth $1,702,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Massmutual Trust Co. FSB ADV boosted its position in Illumina by 83.0% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock worth $26,000 after purchasing an additional 39 shares during the period. Financial Advocates Investment Management boosted its position in Illumina by 1,430.0% during the fourth quarter. Financial Advocates Investment Management now owns 612 shares of the life sciences company’s stock worth $28,000 after purchasing an additional 572 shares during the period. Proficio Capital Partners LLC boosted its position in Illumina by 61.7% during the fourth quarter. Proficio Capital Partners LLC now owns 97 shares of the life sciences company’s stock worth $29,000 after purchasing an additional 37 shares during the period. C J Advisory Inc bought a new position in Illumina during the first quarter worth about $29,000. Finally, Lake Point Wealth Management bought a new position in shares of Illumina in the fourth quarter valued at approximately $30,000. Hedge funds and other institutional investors own 90.51% of the company’s stock.

A number of equities analysts have recently commented on the stock. BidaskClub upgraded shares of Illumina from a “hold” rating to a “buy” rating in a research report on Tuesday, April 16th. Canaccord Genuity restated a “buy” rating and issued a $350.00 price objective (down from $360.00) on shares of Illumina in a research report on Friday. Zacks Investment Research upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $355.00 price objective for the company in a research report on Tuesday, April 2nd. OTR Global lowered shares of Illumina to a “positive” rating in a research report on Tuesday, April 2nd. Finally, Morgan Stanley dropped their target price on shares of Illumina from $320.00 to $288.00 and set an “equal weight” rating for the company in a research report on Monday, January 7th. Two equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $353.58.

In other Illumina news, SVP Charles Dadswell sold 124 shares of Illumina stock in a transaction that occurred on Friday, February 1st. The shares were sold at an average price of $280.11, for a total transaction of $34,733.64. Following the transaction, the senior vice president now directly owns 6,879 shares of the company’s stock, valued at $1,926,876.69. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jay T. Flatley sold 3,300 shares of Illumina stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $321.96, for a total transaction of $1,062,468.00. The disclosure for this sale can be found here. Insiders have sold 34,826 shares of company stock worth $10,665,379 over the last three months. Insiders own 0.38% of the company’s stock.

Illumina stock traded down $1.41 during mid-day trading on Monday, hitting $312.63. 53,448 shares of the company traded hands, compared to its average volume of 930,518. Illumina, Inc. has a one year low of $235.74 and a one year high of $372.61. The firm has a market cap of $46.13 billion, a PE ratio of 54.60, a PEG ratio of 2.24 and a beta of 1.17. The company has a debt-to-equity ratio of 0.23, a current ratio of 2.49 and a quick ratio of 2.27.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, April 25th. The life sciences company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.26. Illumina had a net margin of 25.06% and a return on equity of 24.26%. The business had revenue of $846.00 million during the quarter, compared to analyst estimates of $838.70 million. During the same period in the previous year, the business posted $1.45 earnings per share. Illumina’s revenue for the quarter was up 8.2% on a year-over-year basis. As a group, research analysts anticipate that Illumina, Inc. will post 6.69 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://sportsperspectives.com/2019/04/29/illumina-inc-ilmn-shares-sold-by-meag-munich-ergo-kapitalanlagegesellschaft-mbh.html.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Article: Bull Market

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.